These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 1894582)
21. The role of interleukin-2 in cancer immunotherapy. Eberlein TJ; Schoof DD Compr Ther; 1991 Jan; 17(1):49-56. PubMed ID: 2001612 [TBL] [Abstract][Full Text] [Related]
22. [Quality control of biological therapy in patients with tumors]. Zhang S Zhonghua Yi Xue Za Zhi; 1996 Jul; 76(7):483-4. PubMed ID: 9275493 [No Abstract] [Full Text] [Related]
23. [Adoptive immunotherapy with interleukin-2 and with interleukin-2 activated lymphocytes]. Eggermont AM; Stoter G; Jansen RL; Bolhuis RL Ned Tijdschr Geneeskd; 1989 Jul; 133(28):1387-92. PubMed ID: 2677757 [No Abstract] [Full Text] [Related]
24. Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells. Yasumura S; Lin WC; Hirabayashi H; Vujanovic NL; Herberman RB; Whiteside TL Cancer Res; 1994 Jul; 54(14):3808-16. PubMed ID: 8033100 [TBL] [Abstract][Full Text] [Related]
25. Lymphokine activated killer cells: a new approach to immunotherapy of cancer. Semenzato G Leukemia; 1990 Feb; 4(2):71-80. PubMed ID: 2406518 [No Abstract] [Full Text] [Related]
26. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2. Tzeng JJ; Barth RF; Clendenon NR; Gordon WA Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388 [TBL] [Abstract][Full Text] [Related]
30. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2]. Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896 [TBL] [Abstract][Full Text] [Related]
32. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells. Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722 [TBL] [Abstract][Full Text] [Related]
33. Development of immunotherapy for the treatment of malignancies refractory to conventional therapies. Kim S; Haas GP; Hillman GG Cytokines Mol Ther; 1996 Mar; 2(1):13-9. PubMed ID: 9384685 [TBL] [Abstract][Full Text] [Related]
34. [Immunotherapy of cancer with interleukin-2 and with interleukin-2 activated cells]. Osanto S; Brand A; van Rood JJ; Cleton FJ Ned Tijdschr Geneeskd; 1989 Jul; 133(28):1392-5. PubMed ID: 2677758 [No Abstract] [Full Text] [Related]
36. Natural interleukin-2 and lymphokine activated killer cells in the treatment of neuroblastoma in vitro and in vivo. Berthold F; Himmelmann U; Pohl U Prog Clin Biol Res; 1991; 366():417-24. PubMed ID: 1906185 [No Abstract] [Full Text] [Related]
37. The role of IL-2 in gene therapy. Dalgleish AG Gene Ther; 1994 Mar; 1(2):83-7. PubMed ID: 7584072 [TBL] [Abstract][Full Text] [Related]
38. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells. Thompson JA; Benyunes MC; Bianco JA; Fefer A Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692 [No Abstract] [Full Text] [Related]
39. New perspectives in immunotherapy of leukemia. Lotzová E Immunol Ser; 1994; 61():231-8. PubMed ID: 8011747 [No Abstract] [Full Text] [Related]